PDE4A and diabetes mellitus: Recently, TAK-648, a PDE4 inhibitor, with demonstrated preclinical anti-diabetic properties, has been developed for human T2D (dose prediction using HbA1c results from a db/db mouse study), opening the way for new therapeutic approaches in diabetes [94].